From: Correlates of weight gain during long-term risperidone treatment in children and adolescents
Characteristic | |
---|---|
Psychiatric Diagnoses, n (%) | |
Attention Deficit Hyperactivity Disorder | 96 (87) |
Disruptive Behavior Disorder | 100 (91) |
Anxiety Disorder | 36 (33) |
Tic Disorder | 24 (22) |
Depressive Disorder | 12 (11) |
Pervasive Developmental Disorder | 14 (13) |
Psychotic Disorder | 1 (1) |
Pharmacotherapy | |
Risperidone Dose, mg/d | 1.4 (±1.1) |
Risperidone Dose, mg/kg/d | 0.03 (±0.02) |
Age at Start of Risperidone, yrs | 9.1 (±2.8) |
Treatment Duration, yrs | 2.5 (±1.7) |
Psychostimulants, n (%) | 78 (71) |
Psychostimulants Dose, mg/d a | 59.2 (±28.6) |
Psychostimulants Dose, mg/kg/d a | 1.35 (±0.70) |
Psychostimulants Treatment Duration, yrs | 4.8 (±2.7) |
SSRIs, n (%) | 55 (50) |
  Fluoxetine | 21 (19) |
  Sertraline | 16 (15) |
  Citalopram/Escitalopram | 18 (16) |
SSRI Dose, unit per day b | 1.30 (±0.83) |
SSRI Treatment Duration, yrs | 2.6 (±2.1) |
α2-agonists, n (%) | 35 (32) |